Kessler Topaz Meltzer & Check, LLP is currently investigating potential violations of the federal securities laws on behalf of shareholders of Protagonist Therapeutics, Inc. (NASDAQ: PTGX) (“Protagonist”) securities between February 24, 2021 and September 16, 2021.
Protaganist investors may receive additional information about the investigation by clicking the link "Submit Your Information" above.
Protagonist Therapeutics is a biopharmaceutical company with multiple peptide-based investigational new chemical entities in different stages of development, all derived from its proprietary technology platform. Protagonist’s pipeline includes rusfertide (PTG-300).
On September 17, 2021, Protagonist issued a press release “announc[ing] the receipt of a verbal communication from the U.S. Food and Drug Administration (FDA) that Protagonist's clinical studies for rusfertide, an investigational product candidate currently in development, have been placed on a clinical hold.” The press release further stated that “[t]he clinical hold follows Protagonist’s notification to the FDA of a recent non-clinical finding in a 26-week rasH2 transgenic mouse model study. The rasH2 model is designed to detect signals related to tumorigenicity, and benign and malignant subcutaneous skin tumors were observed in this study.”
Following this news, Protagonist’s stock price fell $28.60 per share, or 62%, to close at $17.53 per share on September 17, 2021.
If you have any questions or would like to discuss this investigation, please contact Kessler Topaz Meltzer & Check, LLP: James Maro, Esq. (484) 270-1453; toll-free at (844) 887-9500; or via e-mail at info@ktmc.com.